Author Index to Volume 15

Aamo, T., 71S
Abbasi, Q.T., 1
Acar, J.F., 61S
Aeschlemann, E.C., 295
Akaniro, J.C., 247
Albert, M.J., 359
Alcaide, F., 291
Aldridge, K.E., 321, 517, 601
Aleksić, S., 213
Alim, A.R.M.A., 359
Allen, S.D., 537
Alsheikhly, A.-R., 569
Altaie, S.S., 579
Anderson, C., 273
Anderson, J., 125
Andriole, V.T., 441
Ansaruzzaman, M., 359
Appelbaum, P.C., 473
Armstrong, S., 103S
Arrieta, A.C., 247
Arzuaga, J.A., 703
Ascher, D.P., 499
Auger, P., 85
Ayats, J., 291

Babinchak, T.J., 367
Bacina, R.M., 587
Bajaksouzian, S., 473
Baker, C.N., 469
Baker, M., 207
Bale, M., 73
Ballow, C.H., 37S
Balows, A., 183, 383, 567
Bañares, R., 703
Baquero, F., 483
Baraia, J., 151
Barg, N.L., 601
Barile, M.F., 411
Barrett, M.S., 169, 259, 379, 459, 641, 685
Barry, A.L., 517
Bartlett, M.S., 129
Basinger, E., 579
Bean, B., 345
Berenguer, J., 151, 703
Berenson, C., 441
Bia, F.J., 121
Bianchi, S., 553
Biganzoli, E., 253
Blumberg, H.M., 545
Bobey, D.G., 595
Boehme, M., 225
Bolan, G., 663
Bolmström, A., 473, 483
Borrell, N., 449
Bortey, E., 511
Bosmans, A., 385
Bouza, E., 151, 287, 703
Bowman, J., 103S
Boyken, L.D., 195
Brackman, M.A., 609
Brambilla, C., 85S
Brinker, J.P., 669
Brissette, E., 5
Brookman, R.R., 579
Brown, D.F.J., 465, 489
Brumfitt, W., 621
Brunden, M.N., 135
Brunham, R., 679
Bryce, E.A., 233

Camaioni, A., 119S
Camus, P., 85S
Cantón, R., 483
Carnahan, A.M., 201
Cavenaghi, L.A., 253
Centor, R.M., 579
Cercenado, E., 151, 287
Chacko, T.M., 121
Chan, K.H., 213
Chan, R.M.T., 85
Chang, J., 411
Chapin-Robertson, K., 645
Chavda, R., 161
Cherubin, C.E., 141
Chin, N.-X., 331, 549, 613
Choo, P.W., 273
Chusid, M.J., 157
Civetta, J., 207
Clark, A., 663
Clark, R.B., 453
Cleary, T., 207
Cleri, D.J., 165
Coldman, A.J., 233
Collins, M.T., 239
Comtois, R., 523
Conly, J.M., 85
Cook, M.B., 225
Costigliola, P., 553
Couillard, M., 313
Coyle, M.B., 399

Dalton, H.P., 511, 579
Daly, S., 89
D'Amato, R.F., 165
Danese, A., 253
Dansey, R.D., 81
Dautzenberg, B., 85S
Davis, T.E., 295
de Bruyn, O., 129S
de Campora, E., 119S
Decurtins, M., 407
Deffez, J.-P., 133S
Denning, D.W., 21
Deschênes, L, 313
DeSilva, H., 125
De Vlieger, A., 123S
Díaz, M.D., 287
Doern, G.V., 633, 669
Domínguez, A., 291
Donahue, M., 5
Dorigan, F.D., 1
Dovey, S.M., 97S
Druart, M., 123S
Duffey, P.S., 109
Dulworth, J.K., 609
Duma, R.J., 49S, 53S
Dumitru, R., 115
Dunne, W.M., 157
Durkin, M.M., 129
Dyke, J., 225

Edberg, S.C., 645
Eisenach, K., 225
Eisenfeld, L, 125
Eliopoulos, G.M., 173
Ellman, M.H., 345
Eng, R.H.K., 141
Eron, L.J., 435
Erwin, M.E., 73, 145, 169, 379, 425, 531, 537, 627, 693
Everaert, L., 91S

Fang, W., 331, 613
Fardella, P., 119S
Farrar, K., 609
Fass, R.J., 367
Felmingham, D., 339
Ferebee, A., 411
Fiaoni, M., 119S
Fischer, G.W., 499
Flock, J.-I., 505
Floyd, M.M., 657
Foleno, B., 375, 557
Fourie, E., 129S
Fraire, A.E., 267
Frederiksen, W., 349
Friedman, B.A., 19S
Fritsche, T.R., 587
Fu, K.P., 375, 557
Fuller, D.D., 295
Furlini, G., 553

Gahrn-Hansen, B., 349
Gantz, N.M., 273
Garber, G.E., 85
Garcia, I., 393
García García, M.I., 67
García-Rodríguez, J.A., 67
García Sánchez, J.E., 67
Gelfand, M.S., 517, 601
Gemmell, C.G., 67S
Gentry, L.O., 435
Gerlach, E.H., 145, 537, 627
Gerson, M., 85
Gervais, A., 523
Gladen, H.E., 99
Godard, P., 85S
Gonzalez, F., 651
Goycoolea, M., 651
Gradon, J.D., 161
Granström, G., 569
Granström, M., 569
Grant, W., 121
Gray, M., 679
Greco, T., 441
Greenberg, S.D., 267

Gretch, D.R., 587
Griffith, B.P., 121
Gu, J.-W., 331, 613
Guay, D.R.P., 39
Guerin, J.C., 85S
Guerra, B., 553
Guijon, F., 679
Gutiérrez, J., 575

Hamilton-Miller, J.M.T., 621
Handl, C.E., 505
Hanson, L.H., 21
Hardy, D.J., 39
Harvey, K.M., 579
Hasan, J.A.K., 201
Hay, M., 81
Heelan, J.S., 5
Hendershot, E.F., 545
Herson, V., 125
Herwaldt, L.A., 195
Hoeprich, P.D., 527
Hollis, R., 195
Hoover, W.W., 259
Hu, P.-c., 411
Hubbard-Shepard, M., 1

Jacka, P.J., 81
Jacobs, M.R., 473
Janda, J.M., 109
Jean-Baptiste, M., 121
Jehl, F., 77S
Joachim, G.R., 165
Jochems, G., 91S
Johnson, B., 225
Johnson, B.A., 579
Johnson, F.B., 673
Johnson, J.R., 399
Johnston, P.E., 11S
Johnston, S.L.G., 355, 363
Joly, J.R., 313
Jones, R.N., 39, 73, 107, 145, 169, 177, 259, 379, 425, 459, 517, 531, 537, 627, 641, 685, 693, 1S, 3S, 49S, 53S
Joseph, S.W., 201

Kagan, I.G., 345
Kapell, K.S., 371
Kapik, B., 135
Kenny, M.T., 609
Kimball, J.L., 493
Klevjer-Anderson, P., 125
Knowles, K., 277
Kocka, F.E., 1
Kohn, G.J., 527
Kolbe, R., 77S
Koontz, F.P., 145, 169, 537, 627, 31S, 43S
Krause, P., 125
Kurzynski, T.A., 493

Lambrecht, R.S., 239
La Place, M., 553
Lau, N.W.H., 213
Lazar, A.M., 125
Leedom, J.M., 55, 57
Lemarie, E., 85S
Leme, I., 195
Lemieux, C., 523
Leon, C., 575
Leonardi, M., 119S
Levi, M., 161
Li, K.I., 561
Libertin, C.R., 115, 281
Linné, S.R., 527
Llompart, I., 449
Löfdahl, S., 569
Lott, T.J., 545
Lousbergh, D., 91S
Low, D.E., 307
Lutwick, L.I., 161

Macaluso, P., 201
Maguire, J.H., 273
Mangi, R.J., 441
Marcelis, L., 385
Marsac, J.H., 81S
Martin, D.H., 663
Martín, E., 575
Martín, R., 291
Martinez, O.V., 207
Martinez-Beltrán, J., 483
Mastellone, A.J., 165
Matamoros, R., 575
Mathew, A., 165
Maybee, D.A., 499
Mayer, G.D., 609
Mayo, D., 125
McDonald, J.C., 277
McGowan, J.E., Jr., 49S, 53S
McLaughlin, J.C., 125
McLeod, M., 67S
McNicol, P., 679
Meier, F.A., 511, 579
Misan, G., 89
Mitra, A.K., 359
Moellering, R.C., Jr., 173
Moncada, J., 663
Monteil, H., 77S
Moseley, S.L., 399
Mroczkowski, T., 663
Muñoz, P., 287
Muñoz Bellido, J.L., 67
Murray, P.R., 537, 627

Nathan, J., 663
Neu, H.C., 331, 549, 613, 1S, 49S, 53S
Newman, L., 561
Ng, M.H., 213
Nilsen, O.G., 71S
Nogales, C., 575

O'Brien, T.F., 49S, 53S
Odontogenic Infections Study Group, The, 133S
Ofloxacin Surveillance Group, The, 425
Olsson, E., 505
Olsson-Liljequist, B., 479
Opal, S.M., 5
Orlando, M.F., 301

Panaro, L., 307
Papa, T.M., 165
Paraskevas, M., 679
Parenti, F., 253
Pascual, A., 393
Peccerillo, K.M., 441
Pechère, J.-C., 111S
Pekkala, D.H., 307
Perea, E.J., 393
Pérez, J.L., 291
Perlman, A.M., 21
Perlman, J., 165
Pfaller, M.A., 145, 195, 537
Pickard, I., 129S
Pierson, C.L., 19S
Pignatari, A., 195
Plá, M.P., 703
Polo, J.R., 703
Pouliot, J., 523
Pritchard, M.F., 307
Pulido, A., 291
Puttemans, M., 91S, 123S

Queener, S.F., 129
Quiroga, T., 651

Raad, I.I., 13
Rabalais, G., 35
Ramazzotti, E., 553
Rand, K.H., 13
Ratner, H., 11S
Re, M.C., 553
Reece, E.A., 645
Reina, J., 449
Reizenstein, E., 569
Reller, L.B., 425
Rezvani, Y., 85S, 133S
Ricchi, E., 553
Rice, L.B., 173
Richards, G.K., 277
Richer, G., 313
Robb, M., 499
Robbins, M.J., 339
Roberts, F.J., 233
Rodriguez, L., 651
Rodriguez-Cintron, W., 267
Rodríguez-Créixems, M., 151, 287
Rodriques, A., 129S
Rosati, L.A., 425
Rose, D., 307
Rosembaum, M., 77S, 85S
Rosenkrantz, T., 125
Rosenthale, M.E., 375
Ryan, J., 441
Ryan, R., 125

Sabath, L.D., 49S, 53S
Sabbagh, M.F., 13
Sampedro, I., 151
Sanchez, M.L., 425, 459
Sanders, C.C., 49S, 53S
Sanson-Fisher, R., 103S
Savidakis, J., 125
Sayahtaheri-Altaie, S., 579
Schaadt, R.D., 417
Schachter, J., 663
Schaffner, W., 11S, 49S, 53S
Scheimberg, A., 77S, 85S, 133S
Schell, R.F., 493
Schentag, J.J., 37S
Schiro, D.D., 601
Schneider, J.P., 157

Schultz, D.A., 493
Schwebke, J., 663
Segreti, J., 371
Sekhon, A.S., 233
Seliborska, Z., 663
Sesso, R., 195
Shafer, M.-A., 663
Shafran, S.D., 85
Shaw, M.A., 129
Sheikh, W., 595
Sherertz, R.J., 13
Shoupe, B.A., 499
Siegel, C., 355, 363
Silcox, V.A., 657
Silver, H., 125
Simoneau, P., 411
Simor, A.E., 307
Smith, C.M., 527
Smith, J.W., 129
Smith, S.M., 141
Sorger, S., 277
Spencer, R.C., 63S
Stager, C.E., 267
Stamm, W.E., 399, 663
Steele, T., 89
Stefansson, E.D., 587
Stein, D.S., 115, 281
Stevens, D.A., 21
Stevens, P.M., 267
Storch, G.A., 301
Stout, G., 35
Strachan, S.A., 81
Stratton, C.W., 321, 11S
Sturman, D., 307
Stutman, H.R., 247
Svarva, P., 71S
Swiatlo, A.L., 1

Tagle, R., 651
Tally, F.P., 53S
Tan, E.N., 141
Tatz, J.S., 561
Tenover, F.C., 49S, 53S
Thauvin Eliopoulos, C., 173
Thomas, P., 89
Thometz, J.G., 157
Thornsberry, C., 457
Thornton, G., 441
Tilyard, M.W., 97S
Toksoz, D., 579
Trenholme, G.M., 371
Tsang, R.S.W., 213
Tuchais, E.M., 85S

Vandeven, J., 385
Van Horn, K.G., 561
van Rensburg, J., 129S
van Schouwenburg, J., 129S
Vargas, O.M., 247
Vautour, R., 633
Verbist, L., 385
Verhaegen, J., 385
Vernaleo, J.R., 165
Vicente, T., 287
Vignoli, M., 553
Villaroel, L., 651
Vinet, B., 523
Visick, E.M., 673

Wakabongo, M., 511, 579
Waldeyer, S., 35
Wallaert, B., 85S
Wallman, A.A., 165
Warren, J.J., 587
Washington, J.A., 145, 537, 627
Weeks, L.S., 321
Welby, P.L., 301
Wellens, K., 363
Wenzel, R.P., 641
Wheat, P.F., 63S
Wong, J.D., 109
Woodley, C.L., 657
Wormser, G.P., 561
Wunderli, W., 407
Wyper, P.A., 307

Yagi, B.H., 417
Yao, J.D.C., 173
Young, L.S., 49S, 53S

Zabransky, R.J., 181
Zahlsen, K., 71S
Zbinden, R., 407
Zierdt, C.H., 185
Zurenko, G.E., 135, 417
Zusag, T.M., 301

DIAGN MICROBIOL INFECT DIS
1992;15:710–722

Subject Index to Volume 15

A-56268. *See* Clarithromycin
Abbott Chlamidiazyme assay, of *Chlamydia trachomatis* from endocervical swabs, 579–586
Abscesses
  erythromycin against, 133S–137S
  α-hemolytic streptococci in, 185–194
  roxithromycin against, 133S–137S
Acetic acid, in α-hemolytic streptococci, 185–194
Acetoin production, in rapid identification of *Aeromonas* spp., 511–515
Acetone smear preparation, in immunofluorescence procedures for detection of human herpesvirus 6 antibodies, 313–320
ACIF. *See* Anticomplement immunofluorescence
Acinetobacter calcoaceticus, cefotaxime against, 85
Acinetobacter lwoffii, cefdinir against, 537–543
Acinetobacter spp.
  cefotaxime against, 69, 89, 94–95
  ceftriaxone against, 89, 93, 95
  cephalosporins against, 67
  fluoroquinolones against, 177–179
  focused microbiologic surveillance of, 11S–18S
  resistance in, 3S–10S
Acquired immunodeficiency syndrome (AIDS)
  clarithromycin against *Mycobacterium avium* in, 47
  gastrointestinal infections and, 383
  Salmonella and *Shigella* in, 1
Actinomyces israelii, cephalosporins against, 60
Actinomyces pyogenes (Corynebacterium pyogenes), human infections with, 349–354
Adenopathy, orodental
  erythromycin against, 133S–137S
  roxithromycin against, 133S–137S
Aeromonas caviae
  elastase activity in, 201–206
  rapid identification of, 511–515
Aeromonas eucrenophila, elastase activity in, 201–206
Aeromonas hydrophila
  elastase activity in, 201–206
  lomefloxacin against, 339–343
  rapid identification of, 511–515
Aeromonas media, elastase activity in, 201–206
Aeromonas schubertii
  elastase activity in, 201–206
  rapid identification of, 511–515
Aeromonas sobria, rapid identification of, 511–515
Aeromonas spp.
  ciprofloxacin against, 453–455
  gentamicin against, 453–455
  imipenem against, 453–455
  meropenem against, 453–455
  rapid identification of, 511–515
  ticarcillin–clavulanate against, 453–455
Aeromonas veronii
  elastase activity in, 201–206
  rapid identification of, 511–515
Agar dilution test
  Aspergillus spp., 27
  cefmetazole in, 627–632
  E-test compared with, 457–472, 483–487
  Neisseria gonorrhoeae, 685–691
  trospectomycin in, 627–632
Agar media, diffusion of teicoplanin and vancomycin in, 253–258
AIDS. *See* Acquired immunodeficiency syndrome
Alkaline-phosphatase-labeled (SNAP) DNA probes, for identification of *Mycobacterium tuberculosis* complex and *Mycobacterium avium* complex, 657–662
AM-1091. *See* CI-960
Amikacin, against mycobacteria, 169–171
Aminocyclitol antibiotics. *See* Trospectomycin
Aminoglycosides
  against pneumonia, 57–65
  resistance to, 3S–18S, 37S–42S
Amoxicillin
  against acute diarrhea, 339–343
  against *Bacteroides fragilis*, 321–330
  clarithromycin compared with, 47–49
Amoxicillin–clavulanic acid
  against respiratory pathogens, 141–144
  roxithromycin compared with, against respiratory tract infections, 85S–89S, 91S–95S
Amphotericin B
  against *Aspergillus* spp., 21–34, 703–706
  against *Candida albicans*, 233–237, 545–547
  flucytosine synergy with, 21–34
  itraconazole synergy with, 21–34
  rifampicin synergy with, 21–34
Ampicillin
  against *Bacteroides fragilis*, 321–330
  against *Chlamydia trachomatis*, 371–373
  clarithromycin compared with, 47–50
  against *Moraxella catarrhalis*, 63S–65S
  national comparative spectrum study of, 425–434
  against pneumonia, 64
  against *Staphylococcus aureus*, 601–608
Ampicillin–sulbactam
  against *Chlamydia trachomatis*, 371–373
  against *Staphylococcus aureus*, 601–608
Anaerobic bacteria, cefotetan resistance in, 595–600
Antibiotics
  emerging trends in resistance to, 1S, 3S–35S, 37S–47S, 49S–60S
  nonadherence to, 103S–109S
  once-daily oral, 61S–79S, 81S–89S, 91S–95S, 97S–101S, 103S–109S, 111S–117S, 119S–127S, 129S–131S, 133S–137S
  pneumonia associated with, 57–65
Antibody-capture enzyme immunoassay, of *Toxoplasma*-specific IgM antibodies, 587–593
Anticomplement immunofluorescence (ACIF), of human herpesvirus 6 antibodies, 313–320
Antilipopolysaccharide, of *Salmonella typhi*, 651–656
Antimicrobials, against mycobacteria, 169–171
API Rapid Strept Identification method, nutritionally deficient streptococci assessed via, 281–285
Arabinose, acid production from, in rapid identification of *Aeromonas* spp., 511–515
Arcanobacterium haemolyticum, Actinomyces pyogenes confused with, 349–354
Arginine, dihydrolation of, in rapid identification of *Aeromonas* spp., 511–515
Arterial catheters, infections of, quantitative tip culture methods in diagnosis of, 13–20
Ascaris lumbricoides, cephalosporins against, 61
Ascitic fluid
  of CL-1 and Cl-2 monoclonal antibodies against serogroup C_1 *Salmonella*, 213–223
  penicillin-resistant enterococci in, 31S–35S
Aspergillus fumigatus
  amphotericin B against, 703–706
  in liver transplant recipients, 703–706
Aspergillus spp., in vitro susceptibility and synergy studies of, 21–34
Azotemia, in *Pneumocystis carinii* pneumonia, 523–526

Bacillus anthracis, cephalosporins against, 61
Bacillus spp., biphasic blood culture system in detection of, 6–8, 11
BACTEC 460 instrumentation, risks to user due to, 181
BACTEC blood culture, in identification of *Staphylococcus aureus* and *Streptococcus pneumoniae*, 295–300
BACTEC high blood volume resin media, evaluation of, 385–391
BACTEC NR6A aerobic blood culture medium, gelatin-supplemented, 277–280
BACTEC PEDS Plus medium, pediatric blood culture evaluation of, 225–231
BACTEC system, in evaluation of pediatric sepsis, 499–503
Bacteremia
  catheter-related, 13–20, 575–578

community-acquired, *Serratia plymuthica* in, 449–452
group-C β-hemolytic streptococci in, 151–155
Bacteroides distasonis, β-lactam agents against, 321–330
Bacteroides fragilis
amoxicillin against, 321–330
cefotaxime against, 70, 89
cefoxitin against, 321–330
ceftriaxone against, 89
cephalosporins against, 60, 75–78
ciprofloxacin against, 613–620
clarithromycin against, 46
clavanulate against, 321–330
CP-74,667 against, 613–620
E3709 against, 621–625
metal compounds against, 549–552
metronidazole against, 321–330
piperacillin against, 321–330
sulbactam against, 321–330
tazobactam against, 321–330
temafloxacin against, 613–620
ticarcillin against, 321–330
tosufloxacin against, 613–620
trospectomycin against, 417–423
Bacteroides ovatus, cefotaxime against, 70
Bacteroides spp.
biphasic blood culture system in detection of, 5
metal compounds against, 549–552
Bacteroides thetaiotamicron
cefotaxime against, 70
β-lactam agents against, 321–330
Bacteroides vulgatus, cefotaxime against, 70
BALB/c mouse model, of *Pneumocystis carinii* infection, 129–134
Bartels reagents, in detection of parainfluenza viruses, 669–672
Bartels Viral Respiratory Panel, in influenza-B virus detection, 35–37
Bartholin's cyst abscess, penicillin-resistant enterococci in, 31S–35S
BGM cells. *See* Buffalo green monkey kidney cells
Bilayer elastin agar medium (BEAM) plate assay, modified, elastolytic activity of *Aeromonas* spp. assessed via, 201–206
Biotyping, in *Escherichia coli* urosepsis, 399–405
Biphasic agar-slide blood culture system, in detection of pseudobacteremia, 5–11
Blastomyces dermatitidis, cephalosporins against, 61
Blood agar, in routine urine culture, 287–290
Blood culture, in microbial resistance surveillance techniques, 31S–35S
Blood culture systems
in identification of *Staphylococcus aureus* and *Streptococcus pneumoniae*, 295–300
pediatric, evaluation of, 301–306, 499–503
yeast in, 233–237
Blood donors, cytomegalovirus antibody detection in, 125–128
Bone infections
Haemophilus influenzae, type f secondary to, 157–159
ofloxacin against, 435–439
Book Reviews
Antiviral Agents and Viral Diseases of Man, 567
Gastrointestinal Infections and AIDS, 383
Human Retrovirology: HTLV, 183
Bordetella parapertussis, clarithromycin against, 43
Bordetella pertussis
clarithromycin against, 45
detection of, 569–573
Bordetella spp., clarithromycin against, 43
Borrelia burgdorferi, clarithromycin against, 43
Brain abscess, α-hemolytic streptococci in, 185–194
Branhamella catarrhalis. *See Moraxella catarrhalis*
Bronchitis
amoxicillin–clavulanic acid against, 85S–89S
clarithromycin against, 39–53
doxycycline against, 123S–127S
pneumonia associated with, 57–65
roxithromycin against, 81S–89S, 123S–27S
Broth microdilution method
Aspergillus spp. and, 26
E-test compared with, 469–472, 483–487
of teicoplanin susceptibility, 609–612
Brucella abortus, carbon substrate utilization patterns of, 109–113
Brucella melitensis, carbon substrate utilization patterns of, 109–113
Brucella spp., carbon substrate utilization patterns of, 109–113
Brucella suis, carbon substrate utilization patterns of, 109–113
Brun–Buisson method, modified, in catheter-related bacteremia and fungemia detection, 575–578
Buffalo green monkey kidney (BGM) cells, in isolation of *Chlamydia trachomatis* in shell vial centrifugation culture, 355–357

Campylobacter coli, clarithromycin against, 46
Campylobacter fetus, clarithromycin against, 46
Campylobacter jejuni
chloramphenicol against, 469–472
ciprofloxacin against, 469–472
clarithromycin against, 46
erythromycin against, 469–472
E-test and, 469–472
gentamicin against, 469–472
lomefloxacin against, 339–343
tetracycline against, 469–472
in 2-year-old girl, 162–163
Campylobacter pylori (*Helicobacter pylori*), clarithromycin against, 43
Candida albicans
amphotericin B against, 545–547
in BACTEC high blood volume resin media, 385–391
biphasic blood culture system in detection of, 5
cefotaxime against, 93
in central venous catheter-related infections, 15, 18
fluconazole against, 545–547
Candida spp.
in blood cultures, 233–237
cefotaxime against, 95
ceftriaxone against, 95
Candida tropicalis
in blood cultures, 233–237
fluconazole against, 545–547
Carbapenems, resistance to, 3S–10S
Carbon substrate utilization patterns, for identification of *Brucella* spp., 109–113
Catheter, peritoneal, penicillin-resistant enterococci in, 31S–35S
Catheter-related infections, detection of, 13–20, 575–578
Cefaclor
against *Haemophilus influenzae*, 49–51, 633–640, 97S–101S
national comparative spectrum study of, 425–434
roxithromycin compared with, against respiratory tract infections, 97S–101S
Cefazolin, resistance to, 37S–42S
Cefdaloxime (HR-916 metabolite, RU29246), against *Haemophilus influenzae*, 693–701
Cefdinir (FK482)
against *Acinetobacter lwofii*, 537–543
against *Enterobacter cloacae*, 537–543
against *Haemophilus influenzae*, 693–701
against *Morganella morganii*, 537–543
against *Neisseria gonorrhoeae*, 685–691
against *Proteus vulgaris*, 537–543
against *Pseudomonas* spp., 537–543
against *Serratia marcescens*, 537–543
against *Staphylococcus* spp., 537–543
against *Streptococcus* group B, 537–543
against *Xanthomonas maltophilia*, 537–543
Cefepime (BMY 28142)
against *Enterobacter* spp., 331–337
against *Haemophilus influenzae*, 633–640
against *Moraxella catarrhalis*, 633–640
against *Streptococcus pneumoniae*, 633–640
Cefetamet
against *Haemophilus influenzae*, 693–701
against *Neisseria gonorrhoeae*, 685–691
Cefixime
against *Haemophilus influenzae*, 49–51
national comparative spectrum study of, 425–434
Cefmetazole
error-rate bounded classification scheme in determination of Z break points for, 138–139
against *Haemophilus influenzae*, 693–701
against *Neisseria gonorrhoeae*, 627–632
Cefoperazone
against *Bacteroides fragilis*, 321–330
against *Chlamydia trachomatis*, 371–373
against pneumonia, 73–80, 441–447
against *Staphylococcus aureus*, 601–608
Cefoperazone–sulbactam
against *Chlamydia trachomatis*, 371–373
against *Staphylococcus aureus*, 601–608

Cefotaxime
ceftriaxone compared with 81–88
against pneumonia, 63–64, 67–88
Cefotetan, predictive value of resistance to, 595–600
Cefoxitin
against *Bacteroides fragilis*, 321–330
resistance to, 3S–10S
Cefpirome, against *Enterobacter* spp., 331–337
Cefpodoxime
against *Haemophilus influenzae*, 693–701
against *Neisseria gonorrhoeae*, 685–691
Cefprozil (BMY 28100)
against *Haemophilus influenzae*, 49–51
Ceftizoxime, against pneumonia, 73–80
Ceftriaxone
cefotaxime compared with, 81–88
against pneumonia, 63, 73–88, 441–447
resistance to, 3S–10S, 37S–42S
Cefuroxime, against respiratory pathogens, 141–144
Cefuroxime axetil, against *Haemophilus influenzae*, 49–51
Cell membrane protein alterations, in antimicrobial resistance, 3S–10S
Cellulitis
erythromycin against, 133S–137S
roxithromycin against, 133S–137S
Cell-wall-deficient streptococci, overview of, 185–194
Central nervous system (CNS), *Haemophilus influenzae*, type f involvement in, 157–159
Central venous catheters, infections of, quantitative tip culture methods in diagnosis of, 13–20
Central venous line sepsis, pediatric, blood cultures in, 499–503
Cephalosporins,
against *Neisseria* spp., 67–72
against *Paragonimus westermanii*, 61
against *Pasturella multocida*, 61
Cephalosporins, third-generation
cost-effective use of, 99–105
against *Haemophilus influenzae*, 49–51, 633–640, 693–701
against *Moraxella catarrhalis*, 633–640
against *Neisseria gonorrhoeae*, 685–691
against pneumonia, 49–51, 55, 57–108
resistance to, 67–72, 3S–10S, 37S–47S, 49S–52S
against *Staphylococcus aureus*, 517–521
against *Streptococcus pneumoniae*, 633–640
Cephamycins, against *Staphylococcus aureus*, 517–521
Cephems, third-generation
activity of, 73–80
resistance to, 3S–10S
Cervical cancer, human papillomavirus association with, 679–683
*Cfo*I, in restriction endonuclease analysis of *Staphylococcus aureus* outbreak, 307–311
CFU. *See* Colony-forming units
Children
blood culture evaluation in, 225–231, 277–280
cholera in, 161–164
influenza-B virus in nasopharyngeal secretions from, 35–37
osteomyelitis and septic arthritis caused by *Haemophilus influenzae*, type f in, 157–159
sepsis in, 499–503
Septi-Chek evaluation in, 301–306
Chlamydia pneumoniae, cephalosporins against, 43, 45, 57–65
Chlamydia psittaci, cephalosporins against, 57–65
Chlamydia spp., clarithromycin against, 43
Chlamydia trachomatis
ampicillin against, 371–373
ampicillin–sulbactam against, 371–373
cefoperazone against, 371–373
cefoperazone–sulbactam against, 371–373
clarithromycin against, 46
doxycycline against, 129S–131S
on endocervical swabs, 579–586
roxithromycin against, 129S–131S
in shell vial centrifugation culture, 355–357
sulbactam against, 371–373
Chloramphenicol
against *Campylobacter jejuni*, 469–472
against pneumococci, 473–478
Cholera, in 2-year-old girl, 161–164
Chloramphenicol, against acute diarrhea, 339–343
Chromosomal DNA, *Staphylococcus aureus*, restriction endonuclease typing of, 195–199
CI-960 (AM-1091, PD127391)
interpretive criteria for disk diffusion tests using 5-μg disks, 379–381
against mycobacteria, 169–171
against *Staphylococcus aureus*, 601–608
Ciprofloxacin
against acute diarrhea, 339–343
against *Aeromonas* spp., 453–455
against *Bacteroides fragilis*, 613–620
against *Campylobacter jejuni*, 469–472
against *Enterococcus faecalis*, 375–378
against *Enterococcus* spp., 459–463
against mycobacteria, 169–171
against *Mycobacterium avium* complex, 367–370
national comparative spectrum study of, 425–434
against norfloxacin-resistant coagulase-negative staphylococci, 557–559
postantibiotic suppressive effect of, 375–378
against *Pseudomonas aeruginosa*, 613–620
against respiratory pathogens, 141–144
resistance to, 177–179
against *Staphylococcus aureus*, 375–378, 517–521, 601–620
against *Staphyococcus epidermidis*, 375–378
against *Staphylococcus* spp., 531–536
against *Streptococcus pneumoniae*, 613–620
against *Streptococcus pyogenes*, 613–620
against *Vibrio* spp., 453–455
against *Xanthomonas maltophilia*, 531–536
Citrobacter diversus
cefotaxime against, 69
cefquinome against, 331–337
Citrobacter freundii
cefotaxime against, 69
cefquinome against, 331–337
cephalosporins against, 74
fluoroquinolones against, 177–178
β-glucuronidase in, 291–294
resistance in, 3S–10S
Citrobacter spp.
cefotaxime against, 68–69
E-test and, 459–463
Cl-1 and Cl-2 murine monoclonal antibodies, against serogroup C_1 *Salmonella*, 213–223
*Cla*I, in restriction endonuclease analysis of *Staphylococcus aureus* outbreak, 307–311
Clarithromycin (A-56268, TE-031)
against *Haemophilus influenzae*, 39–53, 259–266
14-hydroxyclarithromycin interaction with, 259–266
against *Pasturella multocida*, 44–45, 50
pharmacokinetic, microbiologic, and clinical overview of, 39–53
roxithromycin compared with, against respiratory tract infections, 119S–122S
Clavanulate, against *Bacteroides fragilis*, 321–330
CLED agar, in routine urine culture, 287–290
Clindamycin, against *Staphylococcus aureus*, 601–608
Clindamycin 225, against *Pneumocystis* pneumonia, 131
CLOSPYN streptococci, overview of, 185–194
Clonality, of multiple blood and urine isolates in *Escherichia coli* urosepsis, 399–405
Clostridium difficile, clarithromycin against, 46
Clostridium difficile–CUBE test, evaluation of, 493–498
Clostridium perfringens, clarithromycin against, 46
Clostridium spp.
cefotaxime against, 70
clarithromycin against, 46
E3709 against, 621–625
metal compounds against, 549–552
Cloxacillin, against pneumonia, 86
CMV. *See* Cytomegalovirus
CNS. *See* Central nervous system
Coccidioides immitis
cephalosporins against, 61
endospore inhalation in acquisition of, 527–530
pulmonary pseudomycetoma associated with, 267–272
Coliforms
cefotaxime against, 93–95
ceftriaxone against, 95
Colony-forming units (CFU)
in catheter-related infections, 13–20
CLED agar in routine urine culture and, 287–290

Commercial double-test tablet, for screening of *Escherichia coli*, 291–294
Commercial immunologic kits, in identification of *Staphylococcus aureus* and *Streptococcus pneumoniae*, 295–300
Competitive nucleic hybridization assay, for direct detection of *Neisseria gonorrhoeae* in endocervical specimens, 645–649
Continuous ambulatory peritoneal dialysis patients, *Staphylococcus aureus* infection in, 195–199
Conventional broth system, conversion from to biphasic blood culture system in detection of bacteremia, 5–11
Copepods, in perirectal abscess and stool specimens, 561–565
Corynebacterium pyogenes. *See Actinomyces pyogenes*
Corynebacterium spp.
  biphasic blood culture system in detection of, 6–8, 11
  cefotaxime against, 70, 95
  ceftriaxone against, 92, 95
Cost, overall, as part of impact in converting from conventional broth system to biphasic blood culture system in detection of pseudobacteremia, 5–11
Cost-effectiveness, of treatment with third-generation cephalosporins, 99–105
Cotrimoxazole, against *Moraxella catarrhalis*, 63S–65S
Coumermycin, against *Mycobacterium avium* complex, 367–370
Coxiella burnetii, cephalosporins against, 57–65
CP-74,667
  against *Bacteroides fragilis*, 613–620
  against *Pseudomonas aeruginosa*, 613–620
  against *Staphylococcus aureus*, 613–620
  against *Staphylococcus* spp., 531–536
  against *Streptococcus pneumoniae*, 613–620
  against *Streptococcus pyogenes*, 613–620
  against *Xanthomonas maltophilia*, 531–536
Crohn's disease, perirectal abscess in, 561–565
Cryptococcus neoformans, cephalosporins against, 61
Cystic fibrosis sputum, methicillin-resistant *Staphylococcus aureus* derived from, teicoplanin compared with vancomycin against, 247–251
Cytomegalovirus (CMV)
  antibody screening
    in blood donors and mothers of very low birth weight neonates, 125–128
    in transplant donors, 407–409
  pneumonia associated with, 63

Daptomycin, against *Enterococcus faecalis* endocarditis, 173–176
Decaplanin, against *Staphylococcus aureus*, 517–521
Desacetylcefotaxime, against pneumonia, 73–80
Dexamethasone, in immune suppression, 131
DIA. *See* Dot-immunobinding assay
Diarrhea
  amoxicillin against, 339–343
  chloramphenicol against, 339–343
  ciprofloxacin against, 339–343
  Clostridium difficile in, 493–498
  lomefloxacin against, 339–343
  ofloxacin against, 339–343
  sulfamethoxazole against, 339–343
  tetracycline against, 339–343
  trimethoprim against, 339–343
Difluoroquinolones. *See* Lomefloxacin
Diphtheroids
  biphasic blood culture system in detection of, 8
  E3709 against, 621–625
Direct immunofluorescence, in detection of parainfluenza viruses, 669–672
Disk diffusion susceptibility test
  cefmetazole in, 627–632
  E-test compared with, 457–468
  Haemophilus influenzae in, 633–640, 693–701
  Neisseria gonorrhoeae in, 685–691
  ofloxacin in, 425–434
  teicoplanin in, 609–612
  trospectomycin in, 627–632
DNA–DNA hybridization, among nutritionally deficient streptococci, 281–285
DNA–DNA probes, for identification of *Mycobacterium tuberculosis* complex and *Mycobacterium avium* complex, 657–662
DNA fingerprinting, in *Escherichia coli* urosepsis, 399–405
DNA gyrase inhibitors, against *Mycobacterium avium* complex, 367–370
DNA hybridization assay, of pig *Escherichia coli* strains, 505–510
DNA probes
  in diagnosis of pertussis, 569–573
  species-specific, differential detection of *Mycoplasma pulmonis* and *Mycoplasma arthritidis* with, 411–415
DNA–rRNA hybridization assay, for direct detection of *Neisseria gonorrhoeae* in endocervical specimens, 645–649
DNase, staphylococcal, roxithromycin effect on biosynthesis of, 67S–70S
Dot-immunobinding assay (DIA), in diagnosis of *Clostridium difficile*-associated diarrhea, 493–498
Doxycycline, roxithromycin compared with, 123S–127S, 129S–131S
Du Pont Isolater 1.5 system, pediatric blood culture evaluation of, 225–231

E3709
  against *Bacteroides fragilis*, 621–625
  against *Clostridium* spp., 621–625
  against *Enterococcus faecalis*, 621–625
  against *Haemophilus influenzae*, 621–625
  against *Moraxella catarrhalis*, 621–625
EIA. *See* Enzyme immunoassay
Eikenella corrodens
  amoxicillin–clavulanic acid against, 141–144
  cefuroxime against, 141–144
  ciprofloxacin against, 141–144
  enoxacin against, 141–144
  L-ofloxacin against, 141–144
  ofloxacin against, 141–144
Elastase activity, of aeromonads, 201–206
ELISA. *See* Enzyme-linked immunosorbent assay
Embolization, *Neiserria sica* endocarditis with, 165–167
Emphysema, pneumonia associated with, 57–65
Endocarditis
  Enterococcus faecalis, daptomycin and fosfomycin against, 173–176
  group-C β-hemolytic streptococcal bacteremia in, 151–155
  α-hemolytic streptococci in, 185–194
  Neisseria sicca, with embolic phenomena, 165–167
  prosthetic valve, *Salmonella* spp. in, 273–276
  Staphylococcus aureus, nafcillin against, 166
Endocervical infections
  Chlamydia trachomatis on, 579–586
  doxycycline against, 129S–131S
  Neisseria gonorrhoeae in, 645–649
  roxithromycin against, 129S–131S
Endospores, tissue-phase, inhalation of in coccidioidomycosis acquisition, 527–530
Enoxacin
  against norfloxacin-resistant coagulase-negative staphylococci, 557–559
  against respiratory pathogens, 141–144
  against *Staphylococcus aureus*, 517–521, 601–608
  against *Staphylococcus* spp., 531–536
  against *Xanthomonas maltophilia*, 531–536
Enteritis pathogens, lomefloxacin against, 339–343
Enterobacter aerogenes
  cefotaxime against, 69, 87
  ceftriaxone against, 87
  cephalosporins against, 74
Enterobacter cloacae
  cefdinir against, 537–543
  cefotaxime against, 69, 87
  cefquinome against, 331–337
  ceftriaxone against, 87
  cephalosporins against, 74
  fluoroquinolones against, 177–178
  focused microbiologic surveillance of, 11S–18S
  β-glucuronidase in, 291–294
  resistance in, 19S–30S, 37S–42S
Enterobacteriaceae
  cefdinir against, 537–543
  ciprofloxacin against, 531–536
  CP-74667 against, 531–536
  enoxacin against, 531–536
  metal compounds against, 549–552
  norfloxacin against, 531–536
  ofloxacin against, 531–536
Enterobacter spp.
  cefotaxime against, 68–69, 88, 95
  ceftriaxone against, 88, 92–93, 95
  cephalosporins against, 67–73, 75
  E-test and, 459–463

fluoroquinolones against, 177–178
in pediatric blood culture evaluation, 225–231
resistance in, 3S–10S, 31S–35S, 49S–52S
Enterococci
cefotaxime against, 89
ceftriaxone against, 89
ciprofloxacin against, 531–536
CP-74667 against, 531–536
enoxacin against, 531–536
focused microbiologic surveillance of, 11S–18S
hemolysin/bacteriocin produced by, 115–120
multiply-resistant, E-test and, 459–463
norfloxacin against, 531–536
ofloxacin against, 531–536
resistance in, 31S–35S
Enterococcus faecalis
in BACTEC high blood volume resin media, 385–391
cefotaxime against, 70
clarithromycin against, 45
clarithromycin/14-hydroxyclarithromycin against, 259–266
daptomycin against, 173–176
E3709 against, 621–625
fosfomycin against, 173–176
hemolysin/bacteriocin produced by, 115–120
metal compounds against, 549–552
L-ofloxacin against, 375–378
trospectomycin against, 417–423
Enterococcus faecium, metal compounds against, 549–552
Enterococcus spp., E-test and, 459–463
Enzyme immunoassay (EIA)
of antilipopolysaccharide of *Salmonella typhi*, 651–656
of *Chlamydia trachomatis* from endocervical swabs, 579–586
of pig *Escherichia coli* strains, 505–510
of *Toxoplasma*-specific IgM antibodies, 587–593
in urogenital specimens, 663–668
Enzyme-linked immunosorbent assays (ELISA)
of *Chlamydia trachomatis* from endocervical swabs, 579–586
of HTLV-I sera from rural Haiti, 121–124
Eosinophilia, in acute lymphatic filariasis, 345–347
Epidemiology, of antibiotic resistance, 53S–60S
Error-rate bounded classification scheme, in determination of Z break points, 135–140
Erythrocytes, lysis of, enterococcal hemolysin/bacteriocin in, 115–120
Erythromycin
clarithromycin compared with, 44, 47–50
against *Campylobacter jejuni*, 469–472
against *Moraxella catarrhalis*, 63S–65S
against pneumonia, 57–65, 473–478
roxithromycin compared with, against orodental infection, 133S–137S
against *Serratia plymuthica*, 449–452
Escherichia coli
cefotaxime against, 68–69, 82, 87–88, 95
cefquinome against, 331–337
ceftriaxone against, 82, 87–88, 93–95
cephalosporins against, 73, 75
E-test and, 459–463
fluoroquinolones against, 177
focused microbiologic surveillance of, 11S–18S
lomefloxacin against, 339–343
pig, STb assays and, 505–510
rapid identification of, 291–294
trospectomycin against, 417–423
urosepsis, DNA fingerprinting in, 399–405
Esculin hydrolysis, in rapid identification of *Aeromonas* spp., 511–515
E-test
Campylobacter jejuni and, 469–472
challenged with selected strains, 465–468
of difficult-to-test bacteria, 459–463
as epidemiologic tool, 483–487
introduction to, 457–458
minimum inhibitory concentrations and, 479–482
pneumococci and, 473–478
summation of, 489–492
Ethambutol, against mycobacteria, 169–171
Eubacterium spp., clarithromycin against, 46

Fatigue, in acute lymphatic filariasis, 345–347
FATs. *See* Fluorescence antibody tests
Fatty-acid profiling, of bacterial isolates, 19S–30S
FCE 22101, against *Staphylococcus aureus*, 517–521
Femoral catheters, infections of, quantitative tip methods in diagnosis of, 15
Fever, α-hemolytic streptococci in, 185–194
Filariasis, lymphatic, in an American traveler, 345–347
Filter in situ hybridization (FISH), in latent human papillomavirus detection, 679–683
FISH. *See* Filter in situ hybridization
FK482. *See* Cefdinir
Fleroxacin, against *Staphylococcus aureus*, 517–521, 601–608
Fluconazole
against *Candida albicans*, 545–547
against *Candida tropicalis*, 545–547
Flucytosine (fluorocytosine)
amphotericin B synergy with, 21–34
against *Aspergillus* spp., 21–34
Fluorescence antibody tests (FATs)
in EIA of *Chlamydia trachomatis* in urogenital specimens, 663–668
for rapid diagnosis of *Shigella dysentariae* infection, 359–361
Fluorocytosine. *See* Flucytosine
Fluoroquinolones
against *Bacteroides fragilis*, 613–620
against mycobacteria, 169–171
against *Neisseria* spp., 177
against *Pseudomonas aeruginosa*, 613–620
resistance to, 177–179
against *Staphylococcus aureus*, 517–521, 601–608, 613–620
against *Streptococcus pneumoniae*, 613–620
against *Streptococcus pyogenes*, 613–620
Focused microbiologic surveillance
blood culture versus multiple body site monitoring in, 31S–35S
effectiveness of, 49S–52S
overview of, 43S–47S
by specific hospital unit, in defining antimicrobial resistance problems, 12S–18S
Fosfomycin, against *Enterococcus faecalis* endocarditis, 173–176
Francisella tularensis, cephalosporins against, 57–65
Fungemia, catheter-related, detection of, 575–578
Fusobacterium spp.
cefotaxime against, 70
clarithromycin against, 46

Gardnerella vaginalis
cefotaxime against, 70
clarithromycin against, 46
Gas–liquid chromatography, fatty-acid profiling of bacterial isolates via, 19S–30S
Gastrointestinal infections, AIDS and, 383
Gelatin
Actinomyces pyogenes hydrolysis of, 349–354
in blood culture medium, 277–280
Gen-Probe assays, for identification of *Mycobacterium avium* complex, 657–662
Gen-Probe PACE II assay, for direct detection of *Neisseria gonorrhoeae* in endocervical specimens, 645–649
Genital tract infections, *Chlamydia trachomatis* in, 663–668
Gentamicin
against *Aeromonas* spp., 453–455
against *Campylobacter jejuni*, 469–472
against *Enterococcus faecalis*, 173–176
against *Enterococcus* spp., 459–463
against *Serratia plymuthica*, 449–452
against *Staphylococcus aureus*, 601–608
against *Vibrio* spp., 453–455
Giardia lamblia, in 2-year-old girl, 162
Gingival tissue, roxithromycin penetration into, 77S–79S
Glucose
gas formation from, in rapid identification of *Aeromonas* spp., 511–515
in α-hemolytic streptococci, 185–194
β-Glucuronidase
Actinomyces pyogenes production of, 349–354
in *Escherichia coli* screening, 291–294
Glycopeptide compounds, against *Staphylococcus aureus*, 601–608
GN microplates, in determining carbon substrate oxidation, 109–113
Gonorrhea
E-test and, 459–463
trospectomycin against, 417–423
Gram-negative bacilli
biphasic blood culture system in detection of, 5

cefdinir against, 537–543
cephalosporins against, 57–72
ciprofloxacin against, 531–536
clarithromycin against, 46
CP-74667 against, 531–536
emerging trends in resistance to, 1S, 3S–35S, 37S–47S, 49S–60S
enoxacin against, 531–536
fluoroquinolones against, 177–179
β-glucuronidase in, 291–294
norfloxacin against, 531–536
ofloxacin against, 435–439, 531–536
Gram-positive cocci
broth microdilution susceptibility testing of, 609–612
cefdinir against, 537–543
cephalosporins against, 73–80
ciprofloxacin against, 375–378, 531–536
clarithromycin against, 46
CP-74667 against, 531–536
disk diffusion susceptibility testing of, 609–612
enoxacin against, 531–536
fluoroquinolones against, 177–179
mersacidin against, 641–644
metal compounds against, 549–552
norfloxacin against, 375–378, 531–536
L-ofloxacin against, 375–378
ofloxacin against, 425–439, 531–536
roxithromycin against, 67S–70S
vancomycin against, 641–644
Guanine–cytosine values, in α-hemolytic streptococci, 185–194
Gynecologic infections, cefotetan against, 595–600

H9 cells, in assays of HTLV-I sera from rural Haiti, 121–124
Haemophilus influenzae
amoxicillin–clavulanic acid against, 141–144
cefaclor against, 633–640, 97S–101S
cefdaloxime against, 693–701
cefdinir against, 693–701
cefepime against, 633–640
cefetamet against, 693–701
cefixime against, 633–640
cefmetazole against, 693–701
cefotaxime against, 69–70, 81, 83, 87–88, 92–93, 95
cefpodoxime against, 693–701
cefprozil against, 633–640
cefquinome against, 331–337
ceftriaxone against, 81, 83, 87–88, 92, 95
cefuroxime against, 141–144, 633–640
cephalosporins against, 57–65, 73–76, 693–701
ciprofloxacin against, 141–144
clarithromycin against, 39–53
clarithromycin/14-hydroxyclarithromycin against, 259–266
E3709 against, 621–625
enoxacin against, 141–144
fluoroquinolones against, 177
L-ofloxacin against, 141–144
ofloxacin against, 141–144
roxithromycin against, 97S–101S
susceptibility tests of, using *Haemophilus* test medium, 145–150
trospectomycin against, 417–423, 693–701
in unsupplemented NR6A medium, 277–280
Haemophilus parainfluenzae
amoxicillin–clavulanic acid against, 141–144
cefotaxime against, 93, 95
ceftriaxone against, 94–95
cefuroxime against, 141–144
ciprofloxacin against, 141–144
clarithromycin against, 49
enoxacin against, 141–144
L-ofloxacin against, 141–144
ofloxacin against, 141–144
Haemophilus spp.
cefotaxime against, 94
cephalosporins against, 67–72
clarithromycin against, 43
fluoroquinolones against, 177
Haemophilus test medium
quality control guidelines, 145–150
susceptibility tests, 145–150
Helicobacter pylori. *See Campylobacter pylori*
Hemadsorption testing, in influenza detection, 363–365
Hemagglutinin testing, in influenza detection, 363–365
α-Hemolysin
staphylococcal, roxithromycin effect on biosynthesis of, 67S–70S
in streptococci, 185–194
Hemolysin/bacteriocin, enterococcal, as marker of pathogenicity, 115–120
Herpes simplex virus (HSV), detection of, 673–678
HHV-6. *See* Human herpesvirus 6
Hickman catheters, infections of, quantitative tip culture methods in diagnosis of, 15
High-performance liquid chromatography (HPLC), of roxithromycin serum concentration, 71S–76S
*Hind*III, in restriction endonuclease analysis of *Staphylococcus aureus* outbreak, 307–311
Hip, septic arthritis of, *Haemophilus influenzae*, type f in, 157–159
Histoplasma capsulatum, cephalosporins against, 61
HIV. *See* Human immunodeficiency virus
HIV-1. *See* Human immunodeficiency virus type 1
HPLC. *See* High-performance liquid chromatography
HPV. *See* Human papillomavirus
HR-916 metabolite. *See* Cefdaloxime
HRE 664, against *Staphylococcus aureus*, 517–521
HSB-2 cells, human herpesvirus 6 in, 313–320
HSV. *See* Herpes simplex virus
HTLV. *See* Human T-cell lymphotropic virus
HTLV-I. *See* Human T-cell lymphotropic virus type I
Human herpesvirus 6 (HHV-6), immunofluorescence for detection of antibodies against, 313–320
Human immunodeficiency virus (HIV), pneumonia in, 57–65
Human immunodeficiency virus type 1 (HIV-1), vertical transmission of, 553–556
Human papillomavirus (HPV), laboratory diagnosis of, 679–683
Human T-cell lymphotropic virus (HTLV), comprehensive overview of, 183
Human T-cell lymphotropic virus type I (HTLV-I) antibody assays, on sera from rural Haiti, 121–124
14-Hydroxyclarithromycin, clarithromycin with, against *Haemophilus influenzae*, 39–53, 259–266
Hypoglycemia, in *Pneumocystis carinii* pneumonia, 523–526

ICU. *See* Intensive care unit
IFA. *See* Immunofluorescence assay
IgA
antibody, to HIV-1 polypeptides during pregnancy, 553–556
antilipopolysaccharide, of *Salmonella typhi*, 651–656
IgG antilipopolysaccharide, of *Salmonella typhi*, 651–656
IgG_3 murine monoclonal antibodies, against serogroup C_1 *Salmonella*, 213–223
IgM
antilipopolysaccharide, of *Salmonella typhi*, 651–656
Toxoplasma-specific, 587–593
Imipenem
against *Aeromonas* spp., 453–455
against pneumonia, 63
resistance to, 11S–18S
against *Staphylococcus aureus*, 517–521, 601–608
against *Vibrio* spp., 453–455
Immunocompromised patients, pneumonia in, 57–65
Immunofluorescence assay (IFA)
in parainfluenza virus detection, 669–672
rapid viral diagnosis by, 35–37
of *Toxoplasma*-specific IgM antibodies, 587–593
Indicator dye reduction, in determining carbon substrate oxidation, 109–113
Indirect immunofluorescence
in cytomegalovirus antibody detection, 125–128
of HTLV-I sera from rural Haiti, 121–124
of human herpesvirus 6 antibodies, 313–320
in parainfluenza virus detection, 669–672
of *Toxoplasma*-specific IgM antibodies, 587–593
Indole, production of, in screening of *Escherichia coli*, 291–294
Infants. *See* Neonates
Infections, catheter-related, quantitative tip culture methods in diagnosis of, 13–20
Influenza, hemagglutination and hemad-

sorption tests in detection of, 363–365
Influenza-B virus, immunofluorescence in rapid detection of, 35–37
Inoculated mouse model, of *Pneumocystis carinii* infection, 129–134
Intensive care unit (ICU)
cefotaxime versus ceftriaxone in, 89–97
Enterobacter cloacae infections in, 37S–42S
focused microbiologic surveillance in, 11S–18S
pathogens, susceptibility among, 19S–30S
Internal jugular catheters, infections of, quantitative tip culture methods in diagnosis of, 15
Interpretive criteria, for lomefloxacin and meropenem in susceptibility tests of *Haemophilus influenzae* using *Haemophilus* test medium, 145–150
Intraabdominal infection
cefotetan against, 595–600
group-C β-hemolytic streptococcal bacteremia in, 151–155
In vitro fertilization, endocervical infections during, roxithromycin and doxycycline against, 129S–131S
Iron concentrations, in mycobactin dependence in *Mycobacterium paratuberculosis*, 239–246
Isepamicin, against mycobacteria, 169–171
Isolater system, in evaluation of pediatric sepsis, 499–503
Isoniazid, against mycobacteria, 169–171
Itraconazole
amphotericin B synergy with, 21–34
against *Aspergillus* spp., 21–34

JM-1397, against aerobic and anaerobic bacteria, 549–552
JM-2469, against aerobic and anaerobic bacteria, 549–552
Joint infections, *Haemophilus influenzae*, type f secondary to, 157–159
Josamycin, clarithromycin compared with, 47–49

Kanamycin, against mycobacteria, 169–171
Ketoconazole, against *Aspergillus* spp., 21–34
Klebsiella oxytoca
cefotaxime against, 68–69, 87
cefquinome against, 331–337
ceftriaxone against, 87
Klebsiella pneumoniae
amoxicillin–clavulanic acid against, 141–144
cefotaxime against, 68–69, 81, 87–88
cefquinome against, 331–337
ceftriaxone against, 81, 87–88
cefuroxime against, 141–144
in central venous catheter-related infections, 16, 19
cephalosporins against, 73, 75–76
ciprofloxacin against, 141–144
enoxacin against, 141–144
fluoroquinolones against, 177
L-ofloxacin against, 141–144
ofloxacin against, 141–144, 425–434
Klebsiella spp.
cefotaxime against, 68–69, 92, 95
cefquinome against, 331–337
ceftriaxone against, 93–95
cephalosporins against, 74, 77
focused microbiologic surveillance of, 11S–18S

β-Lactam antibiotics
against *Bacteroides fragilis*, 321–330
against *Chlamydia trachomatis*, 371–373
resistance to, 3S–10S, 19S–35S, 37S–47S, 49S–52S
against *Staphylococcus aureus*, 517–521
β-Lactamase inhibitors, against *Bacteroides fragilis*, 321–330
β-Lactamases, in Enterobacteriaceae, 459–463
Lactic acid, in α-hemolytic streptococci, 185–194
Latex agglutination test
in *Clostridium difficile*-associated diarrhea detection, 493–498
in cytomegalovirus antibody detection, 125–128, 407–409
for grouping *Salmonella* and *Shigella*, 1–4
Legg–Calve Perthe's disease, osteomyelitis and septic arthritis secondary to *Haemophilus influenzae*, type f in, 157–159
Legionella micdadei, clarithromycin against, 44, 46
Legionella pneumophilia
amoxicillin–clavulanic acid against, 141–144
cefuroxime against, 141–144
ciprofloxacin against, 141–144
clarithromycin against, 44–45, 47
enoxacin against, 141–144
L-ofloxacin against, 141–144
ofloxacin against, 141–144
Legionella spp., clarithromycin against, 43–44
Leuconostoc spp.
mersacidin against, 641–644
vancomycin against, 641–644
L-form streptococci
genetic heterogeneity among, 281–285
overview of, 185–194
Light microscopy, of α-hemolysin-deficient streptococci, 185–194
Lipopolysaccharide (LPS), chlamydial, polyclonal antibody to, 663–668
Listeria monocytogenes
cefotaxime against, 70, 89
ceftriaxone against, 89
clarithromycin against, 44, 46–47
Liver transplantation, *Aspergillus fumigatus* infection after, 703–706
Lomefloxacin
against acute diarrhea, 339–343
against *Aeromonas hydrophila*, 339–343
against *Campylobacter jejuni*, 339–343
against *Escherichia coli*, 339–343
against *Haemophilus influenzae*, 145–150
intracellular penetration of, 393–398
resistance to, 177–179
against *Salmonella* spp., 339–343
against *Shigella* spp., 339–343
against *Vibrio* spp., 339–343
against *Yersinia enterocolitica*, 339–343
Lymphatic filariasis, acute, in an American traveler, 345–347
Lymphedema, of arm and chest wall, in acute lymphatic filariasis, 345–347
Lysine, decarboxylation of, in rapid identification of *Aeromonas* spp., 511–515

M87-1551. *See* Mersacidin
MacConkey agar, in routine urine culture, 287–290
Macrodilution broth method, in *Aspergillus* spp. susceptibility and synergy studies, 21–34
Macrolides. *See* Roxithromycin
Macrophages
lomefloxacin in, 393–398
temafloxacin in, 393–398
Maki's method, in catheter-related bacteremia and fungemia detection, 575–578
Mannitol, acid production from, in rapid identification of *Aeromonas* spp., 511–515
Mannitol–salt–oxacillin–tellurite medium, in isolation of methicillin-resistant *Staphylococcus aureus* from contaminated sources, 207–211
MBCs. *See* Minimum bactericidal concentrations
McCoy cells, in isolation of *Chlamydia trachomatis* in shell vial centrifugation culture, 355–357
MDL 62211, against *Staphylococcus aureus*, 517–521
Meningitis, group-C β-hemolytic streptococcal bacteremia in, 151–155
Meropenem
against *Aeromonas* spp., 453–455
against *Haemophilus influenzae*, 145–150
against *Staphylococcus aureus*, 517–521
against *Vibrio* spp., 453–455
Mersacidin (M87-1551)
against *Leuconostoc* spp., 641–644
against *Pediococcus* spp., 641–644
against *Staphylococcus aureus*, 517–521, 641–644
against *Staphylococcus haemolyticus*, 641–644
Mesosomes, in α-hemolytic streptococci, 185–194
Metal compounds, against aerobic and anaerobic bacteria, 549–552
Methanol fixation, in immunofluorescence procedures for detection of human herpesvirus 6 antibodies, 313–320
Methicillin, staphylococcal resistance to, 207–251, 465–468, 549–552, 601–608
Metronidazole
against *Bacteroides fragilis*, 321–330
against pneumonia, 64
Mezlocillin, resistance to, 37S–42S
MFCs. *See* Minimum fungicidal concentrations
Miconazole, against *Aspergillus* spp., 21–34
Microbial resistance surveillance

blood culture versus multiple body site monitoring in, 31S–35S
effectiveness of, 49S–52S
overview of, 43S–47S
by specific hospital unit, in defining antimicrobial resistance problems, 11S–18S
Microbiologic assay, of roxithromycin serum concentration, 71S–76S
Microdilution broth method, quantitative antimicrobial susceptibility tests performed via, 166
Microdilution technique, DNA gyrase inhibitor effect on *Mycobacterium avium* complex assessed via, 367–370
Microwell enzyme immunosorbent assay, of *Chlamydia trachomatis* in urogenital specimens, 663–668
MICs. *See* Minimum inhibitory concentrations
Minimum bactericidal concentrations (MBCs)
cefquinome, 331–337
ciprofloxacin, 367–370
coumermycin, 367–370
CP-74,667, 613–620
DNA gyrase inhibitors, 367–370
novobiocin, 367–370
penicillin, 166
Minimum fungicidal concentrations (MFCs)
amphotericin B, 21–34
flucytosine, 21–34
itraconazole, 21–34
ketoconazole, 21–34
saperconazole, 21–34
Minimum inhibitory concentrations (MICs)
amikacin, 166, 170–171
aminoglycosides, 3S–10S, 37S–42S
amoxicillin, 321–330, 339–343
amoxicillin–clavulanic acid, 141–144
amphotericin B, 21–34, 233–237
ampicillin, 166, 321–330, 371–373, 601–608, 63S–65S
ampicillin–sulbactam, 371–373, 601–608
carbenicillin, 166
carbapenems, 3S–10S
cefaclor, 633–640
cefazolin, 37S–42S
cefdaloxime, 693–701
cefdinir, 537–543, 685–701
cefepime, 331–337, 633–640
cefetamet, 685–701
cefixime, 633–640
cefmetazole, 627–632, 693–701
cefoperazone, 73–80, 166, 321–330, 371–373, 601–608
cefoperazone–sulbactam, 371–373, 601–608
cefotaxime, 68–71, 73–84, 89–97, 166
cefoxitin, 166, 321–330, 3S–10S
cefpirome, 331–337
cefpodoxime, 685–701
cefprozil, 633–640
cefquinome, 331–337
ceftazidime, 73–80, 331–337, 3S–10S, 37S–42S
ceftizoxime, 73–80
ceftriaxone, 73–84, 89–97, 3S–10S, 37S–42S
cefuroxime, 141–144, 633–640
cephalosporins, 517–521, 693–701, 3S–10S, 37S–42S
cephalothin, 166
cephamycin, 517–521
cephems, 3S–10S
chloramphenicol, 339–343, 473–478
CI-960, 170–171, 379–381, 601–608
ciprofloxacin, 141, 170–171, 179, 339–378, 453–455, 531–536, 559, 601–608, 613–620
clarithromycin, 39–53, 259–266
clavanulate, 321–330
clindamycin, 166, 601–608
CP-74,667, 531–536, 613–620
cotrimoxazole, 63S–65S
coumermycin, 367–370
daptomycin, 173–176
decaplanin, 517–521
desacetylcefotaxime, 73–80
DNA gyrase inhibitors, 367–370
E3709, 621–625
enoxacin, 141, 517–521, 531–536, 557–559, 601–608
erythromycin, 166, 473–478, 63S–65S
E-test and, 465–482
ethambutol, 170–171
FCE 22101, 517–521
fleroxacin, 517–521, 601–608
fluconazole, 545–547
flucytosine, 21–34
fluoroquinolone, 177–179, 517–521, 531–536, 613–620
fosfomycin, 173–176
gentamicin, 166, 453–455, 601–608
glycopeptide compound, 601–608
HRE 664, 517–521
14-hydroxyclarithromycin, 259–266
imipenem, 453–455, 517–521, 601–608
isepamicin, 170–171
isoniazid, 170–171
itraconazole, 21–34
JM-1397, 549–552
JM-2469, 549–552
kanamycin, 170–171
ketoconazole, 21–34
β-lactam, 517–521
lomefloxacin, 146–150, 177–179, 339–343
MDL 62211, 517–521
meropenem, 146–150, 453–455, 517–521
mersacidin, 517–521, 641–644
metronidazole, 321–330
mezlocillin, 37S–42S
miconazole, 21–34
mupirocin, 517–521, 601–608
norfloxacin, 170–171, 375–378, 517–521, 531–536, 557–559, 601–608
novobiocin, 367–370
L-ofloxacin, 141–144, 375–378, 557–559
ofloxacin, 141–144, 359–343, 517–521, 531–536, 601–608
penicillin, 63, 166, 473–478, 3S–10S, 37S–42S
peptide/peptide-derivative compound, 517–521
piperacillin, 166, 321–330, 517–521, 3S–10S, 37S–42S
quinolone, 517–521
ramoplanin, 517–521, 601–608
rifampicin, 170–171
rifampin, 601–608
Ro 23-9424, 517–521
roxithromycin, 63S–70S
saperconazole, 21–34
sparfloxacin, 170–171
sulbactam, 321–330, 371–373
sulfamethoxazole, 339–343
tazobactam, 321–330, 517–521
teicoplanin, 247–258, 517–521, 601–612
temafloxacin, 613–620
tetracycline, 339–343, 473–478, 601–608, 63S–65S
ticarcillin, 321–330
ticarcillin–clavulanate, 453–455
tosufloxacin, 613–620
trimethoprim, 339–343
trimethaprim-sulfamethoxazole, 63S–65S, 166, 601–608
trospectomycin, 417–423, 627–632, 693–701
vancomycin, 166, 247–258, 517–521, 601–608, 641–644
WIN 57273, 170–171, 517–521, 601–608
Mink lung cells, herpes simplex virus detection in, 673–678
Modified conventional tests, in identification of *Staphylococcus aureus* and *Streptococcus pneumoniae*, 295–300
Monoclonal antibodies, in detection of parainfluenza viruses, 669–672
Moraxella catarrhalis (*Branhamella catarrhalis*)
amoxicillin–clavulanic acid against, 141–144
cefaclor against, 633–640, 97S–101S
cefepime against, 633–640
cefixime against, 633–640
cefotaxime against, 70, 87
cefprozil against, 633–640
ceftriaxone against, 87
cefuroxime against, 141–144, 633–640
cephalosporins against, 57–65, 74–75, 78
ciprofloxacin against, 141–144
clarithromycin against, 44–45, 49
E3709 against, 621–625
enoxacin against, 141–144
L-ofloxacin against, 141–144
ofloxacin against, 141–144
roxithromycin against, 63S–65S, 67S, 97S–101S
trospectomycin against, 417–423
Moraxella spp.
cefquinome against, 331–337
clarithromycin against, 43
fluoroquinolones against, 177
Morganella morganii
cefdinir against, 537–543
cefotaxime against, 68–69
Morganella spp.
cefotaxime against, 69
cefquinome against, 331–337
resistance in, 3S–10S

MT-2 cells, in assays of HTLV-I sera from rural Haiti, 121–124
Multiple body site monitoring, in microbial resistance surveillance techniques, 31S–35S
Mupirocin, against *Staphylococcus aureus*, 517–521, 601–608
Mycobacterium avium complex
ciprofloxacin against, 367–370
clarithromycin against, 46
coumermycin against, 367–370
DNA–DNA probes for identification of, 657–662
DNA gyrase inhibitors against, 367–370
novobiocin against, 367–370
Mycobacterium avium–intracellulare
amikacin against, 169–171
CI-960 against, 169–171
ciprofloxacin against, 169–171
ethambutol against, 169–171
isepamicin against, 169–171
isoniazid against, 169–171
kanamycin against, 169–171
norfloxacin against, 169–171
rifampin against, 169–171
sparfloxacin against, 169–171
WIN 57273 against, 169–171
Mycobacterium chelonae
amikacin against, 169–171
CI-960 against, 169–171
ciprofloxacin against, 169–171
ethambutol against, 169–171
isepamicin against, 169–171
isoniazid against, 169–171
kanamycin against, 169–171
norfloxacin against, 169–171
rifampin against, 169–171
sparfloxacin against, 169–171
WIN 57273 against, 169–171
Mycobacterium fortuitum
amikacin against, 169–171
CI-960 against, 169–171
ciprofloxacin against, 169–171
clarithromycin against, 46
ethambutol against, 169–171
isepamicin against, 169–171
isoniazid against, 169–171
kanamycin against, 169–171
norfloxacin against, 169–171
rifampin against, 169–171
sparfloxacin against, 169–171
WIN 57273 against, 169–171
Mycobacterium kansasii, clarithromycin against, 46
Mycobacterium leprae, clarithromycin against, 46
Mycobacterium paratuberculosis, mycobactin dependence in, 239–246
Mycobacterium tuberculosis
cephalosporins against, 57–65
clarithromycin against, 46
DNA–DNA probes for identification of, 657–662
Mycobacterium xenopi, clarithromycin against, 46
Mycobactin dependence, in *Mycobacterium paratuberculosis*, 239–246
Mycolic acid analysis, for identification of *Mycobacterium avium* complex, 657–662
Mycoplasma arthritidis, differential diagnosis between *Mycoplasma pulmonis* and, 411–415
Mycoplasma growth agar, α-hemolytic streptococci grown in, 185–194
Mycoplasma hominis
clarithromycin against, 46
doxycycline against, 129S–131S
roxithromycin against, 129S–131S
Mycoplasma pneumoniae
cephalosporins against, 58
clarithromycin against, 43, 45
Mycoplasma pulmonis, differential diagnosis between *Mycoplasma arthritidis* and, 411–415
Mycoplasma spp., clarithromycin against, 43

Nafcillin
against pneumonia, 64
against *Staphylococcus aureus* endocarditis, 166
Naphthyridines, fluorinated, against *Staphylococcus aureus*, 517–521
Nasopharyngeal secretions
Bordetella pertussis in, 569–573
immunofluorescence assay in detection of influenza-B virus in, 35–37
National Committee for Clinical Laboratory Standards, M23-T guidance of, for *Haemophilus* test medium use, 145–150
National Nosocomial Resistance Surveillance Group, report of, on trends in antibiotic utilization and bacterial resistance, 37S–42S
NDA. *See* New Drug Application
Necrotizing fascitis, *Aspergillus fumigatus* infection mimicking, 703–706
Neisseria gonorrhoeae
cefdinir against, 685–691
cefetamet against, 685–691
cefotaxime against, 70
cefpodoxime against, 685–691
cefquinome against, 331–337
clarithromycin against, 46
in endocervical specimens, 645–649
E-test and, 459–463
trospectomycin against, 417–423
Neisseria meningitidis
cefotaxime against, 70, 95
ceftriaxone against, 92, 95
sodium polyanetheolesulfonate effect on isolation of, 277–280
Neisseria sicca endocarditis, with embolic phenomena, 165–167
Neisseria spp.
cephalosporins against, 67–72
fluoroquinolones against, 177
Neonates
nursery outbreak of *Staphylococcus aureus* among, 307–311
very low birth weight, cytomegalovirus antibody detection in mothers of, 125–128
New Drug Application (NDA), for clarithromycin, 39–53
Nocardia spp., pneumonia associated with, 63
Nonadherence, to antibiotics, factors affecting, 103S–109S
Norfloxacin
against coagulase-negative staphylococci, 557–559
against *Enterococcus faecalis*, 375–378
against mycobacteria, 169–171
national comparative spectrum study of, 425–434
postantibiotic suppressive effect of, 375–378
against *Staphylococcus aureus*, 375–378, 517–521, 601–608
against *Staphyococcus epidermidis*, 375–378
against *Staphylococcus* spp., 531–536
against *Xanthomonas maltophilia*, 531–536
Nosocomial bacteremia
biphasic blood culture system impact on incidence of, 5–11
resistance among, 3S–10S, 31S–35S, 37S–42S
Novobiocin, against *Mycobacterium avium* complex, 367–370
Nursing homes, pneumonia in, 57–65
Nutritionally deficient streptococci
genetic heterogeneity among, 281–285
overview of, 185–194

L-Ofloxacin
against *Enterococcus faecalis*, 375–378
against norfloxacin-resistant coagulase-negative staphylococci, 557–559
postantibiotic suppressive effect of, 375–378
against respiratory pathogens, 141–144
against *Staphylococcus aureus*, 375–378
against *Staphyococcus epidermidis*, 375–378
Ofloxacin
against acute diarrhea, 339–343
against *Klebsiella pneumoniae*, 425–434
national comparative spectrum study of, 425–434
against *Providencia* spp., 425–434
against *Pseudomonas aeruginosa*, 435–439
against respiratory pathogens, 141–144
against *Serratia marcescens*, 425–434
against *Staphylococcus aureus*, 517–521, 601–608
against *Staphylococcus* spp., 531–536
against *Xanthomonas maltophilia*, 531–536
Organ transplantation
Aspergillus fumigatus infection after, 703–706
cytomegalovirus antibody screening of donors prior to, 407–409
Ornithine, decarboxylation of, in rapid identification of *Aeromonas* spp., 511–515
Orodental infection, acute
erythromycin against, 133S–137S
roxithromycin against, 133S–137S
Otitis media, roxithromycin against, 119S–122S
Osteomyelitis
ofloxacin against, 435–439

of proximal femur, *Haemophilus influenzae*, type f in, 157–159
Oxacillin
against pneumonia, 64
Staphylococcus aureus resistance to, 517–521
Oxazolidinones. *See* E3709

p24 antigenemia, during pregnancy, 553–556
Pancreatic abscess, penicillin-resistant enterococci in, 31S–35S
Paracoccidioides brasiliensis, cephalosporins against, 61
Paragonimus westermanii, cephalosporins against, 61
Parainfluenza virus (PIV), detection of, 363–365, 669–672
PASCO semiautomatic broth microdilution system, E-test compared with, 483–487
Pasturella multocida
cephalosporins against, 61
clarithromycin against, 44–45, 50
pB23, in detection of pertussis, 569–573
PCR. *See* Polymerase chain reaction
PD127391. *See* CI-960
Pediatric blood culture
evaluation, of BACTEC PEDS Plus and Du Pont Isolater 1.5 systems, 225–231
medium, gelatin-supplemented, 277–280
Pediococcus spp.
mersacidin against, 641–644
vancomycin against, 641–644
Pelvic inflammatory disease, trospectomycin against, 417–423
Penicillin
clarithromycin compared with, 47–49
Enterococcus spp. resistance to, 459–463
gonococci with chromosomal-mediated resistance to, 685–691
against group-C β-hemolytic streptococcal bacteremia, 151–155
against pneumonia, 57–65, 473–478
resistance to, 3S–10S, 31S–35S, 37S–42S
Pentamidine, against *Pneumocystis carinii* pneumonia, 523–526
Peptide/peptide-derivative compounds, against *Staphylococcus aureus*, 517–521
Peptostreptococcus spp., cefotaxime against, 70
Pericarditis, metastatic suppurative, group-C β-hemolytic streptococcal bacteremia in, 151–155
Pericoronitis
erythromycin against, 133S–137S
roxithromycin against, 133S–137S
Perirectal abscess, copepods in, 561–565
Peritoneal catheter, penicillin-resistant enterococci in, 31S–35S
Peritoneal macrophages
lomefloxacin in, 393–398
temafloxacin in, 393–398
Pertussis, diagnosis of, 569–573
pGEM series vectors, in differential diagnosis between *Mycoplasma pulmonis* and *Mycoplasma arthritidis*, 411–415
pH, in mycobactin dependence in *Mycobacterium paratuberculosis*, 239–246
Phage typing, in epidemiology of *Staphylococcus aureus* outbreak, 307–311
Phagocytes
lomefloxacin in, 393–398
temafloxacin in, 393–398
Phagocytosis, *Streptococcus pneumoniae* susceptibility to, 67S–70S
Pharyngitis
clarithromycin against, 39–53
roxithromycin against, 81S–84S
Pharyngotonsillitis, roxithromycin against, 119S–122S
Phorbol myristate acetate, PMN association of quinolones increased by, 393–398
Pig intestinal loop (PIL) assay, of pig *Escherichia coli* strains, 505–510
PIL assay. *See* Pig intestinal loop assay
Piperacillin
against *Bacteroides fragilis*, 321–330
resistance to, 3S–10S, 37S–42S
against *Staphylococcus aureus*, 517–521
PIV. *See* Parainfluenza virus
Plasmid analysis, in *Escherichia coli* urosepsis, 399–405
Plasmid DNA, *Staphylococcus aureus*, restriction endonuclease typing of, 195–199
PLATELIA Toxo IgM enzyme immunoassay, of *Toxoplasma*-specific IgM antibodies, 587–593
PMNs. *See* Polymorphonuclear leukocytes
Pneumococcal polysaccharide, roxithromycin effect on biosynthesis of, 67S–70S
Pneumococci, E-test in susceptibility testing of, 473–478
Pneumocystis carinii pneumonia
cephalosporins against, 57–65
inoculated mouse model of infection with, 129–134
pentamidine levels in, 523–526
Pneumolysin, roxithromycin effect on biosynthesis of, 67S–70S
Pneumonia
amoxicillin–clavulanic acid against, 85S–89S
cefotaxime versus ceftriaxone against, 81–88
cefperazone against, 441–447
ceftriaxone against, 441–447
cephalosporins against, 55, 57–65, 67–97, 99–105, 107–108
clarithromycin against, 39–53
clindamycin 225 against, 131
group-C β-hemolytic streptococcal bacteremia in, 151–155
inoculated mouse model of infection with, 129–134
pentamidine levels in, 523–526
primaquine 2 against, 131
roxithromycin against, 85S–89S
trimethoprim–sulfamethoxazole against, 129–134
WR238605 1 against, 131
Pneumoslide, in identification of *Streptococcus pneumoniae*, 295–300
Polyclonal antibody, to chlamydial lipopolysaccharide, 663–668
Polymerase chain reaction (PCR), in latent human papillomavirus detection, 679–683
Polymorphonuclear leukocytes (PMNs)
lomefloxacin in, 393–398
temafloxacin in, 393–398
Postantibiotic effect
of E3709, 621–625
of L-ofloxacin, 375–378
of trospectomycin, 417–423
pRZ61, in detection of pertussis, 569–573
Pregnancy, prognostic value of IgA antibody to HIV-1 polypeptides during, 553–556
Primaquine 2, against *Pneumocystis* pneumonia, 131
Propionobacterium acnes, clarithromycin against, 46
Propionobacterium spp., clarithromycin against, 46
Prosthetic valve endocarditis, *Salmonella* spp. in, 273–276
Proteus mirabilis
cefotaxime against, 68–69, 95
cefquinome against, 331–337
ceftriaxone against, 94–95
cephalosporins against, 73
Proteus spp.
cefotaxime against, 68–69
cephalosporins against, 75
Proteus vulgaris
cefdinir against, 537–543
cefotaxime against, 68–69
cephalosporins against, 76
resistance in, 3S–10S
Providencia rettgeri, cefotaxime against, 69
Providencia spp.
cefotaxime against, 69
cefquinome against, 331–337
ofloxacin against, 425–434
resistance in, 3S–10S
Providencia stuartii, cefotaxime against, 69
Proximal femur, osteomyelitis of, *Haemophilus influenzae*, type f in, 157–159
Pseudobacteremia, incidence of, impact of converting to biphasic blood culture system on, 5–11
Pseudomonas aeruginosa
amoxicillin–clavulanic acid against, 141–144
in BACTEC high blood volume resin media, 385–391
cefotaxime against, 68–69, 88, 93, 95
cefquinome against, 331–337
ceftriaxone against, 93, 95
cefuroxime against, 141–144
in central venous catheter-related infections, 16
cephalosporins against, 62, 64, 73–80
ciprofloxacin against, 141–144
enoxacin against, 141–144
fluoroquinolones against, 177–178
focused microbiologic surveillance of, 11S–18S
L-ofloxacin against, 141–144

ofloxacin against, 141–144, 435–439
resistance in, 3S–10S, 19S–30S, 37S–42S, 49S–52S
Pseudomonas cepacia, cefotaxime against, 69
Pseudomonas fluorescens, cefotaxime against, 69
Pseudomonas pseudomallei, cephalosporins against, 61
Pseudomonas putida, cefotaxime against, 69
Pseudomonas spp.
cefdinir against, 537–543
cefotaxime against, 89
cefquinome against, 331–337
ceftriaxone against, 89
cephalosporins against, 67–72
fluoroquinolones against, 179
resistance in, 3S–10S
Pseudomonas stutzeri, cefotaxime against, 69
Pulmonary coccidioidal pseudomycetoma, overview of, 267–272
Pyelonephritis, acute, *Escherichia coli* in, 399–405
Pyrazinamide hydrolysis, in rapid identification of *Aeromonas* spp., 511–515
Pyridoxal dependent streptococci
genetic heterogeneity among, 281–285
overview of, 185–194

Quality control guidelines, for lomefloxacin and meropenem in susceptibility tests of *Haemophilus influenzae* using *Haemophilus* test medium, 145–150
Quantitative blood cultures, in pediatric sepsis, 499–503
Quantitative tip culture methods, in diagnosis of central venous catheter-related infections, 13–20
Quinolones
intracellular penetration of, 393–398
against mycobacteria, 169–171
against norfloxacin-resistant coagulase-negative staphylococci, 557–559
against pneumonia, 63–64
resistance to, 177–179
against respiratory pathogens, 141–144
against *Staphylococcus aureus*, 517–521

Radiometric growth assay, of mycobactin dependence in *Mycobacterium paratuberculosis*, 239–246
Ramoplanin, against *Staphylococcus aureus*, 517–521, 601–608
Rapid culture method, for herpes simplex virus detection, 673–678
Rapid smear drying, in immunofluorescence procedures for detection of human herpesvirus 6 antibodies, 313–320
Receiver operating (ROC) curves, for diagnostic usefulness of ELISA test compared to Widal test, 651–656
Rectal swabs, penicillin-resistant enterococci in, 31S–35S
Recurrent aphthous stomatitis, α-hemolytic streptococci in, 185–194
Respiratory tract infections
amoxicillin–clavulanic acid against, 85S–95S
cefaclor against, 97S–101S
clarithromycin against, 39–53, 119S–122S
doxycycline against, 123S–127S
Moraxella catarrhalis in, 63S–65S
ofloxacin against, 425–439
roxithromycin against, 81S–89S, 91S–95S, 97S–101S, 111S–127S
Serratia plymuthica in, 449–452
trospectomycin against, 417–423
Respiratory viruses, in nasopharyngeal secretions, immunofluorescence assay in detection of, 35–37
Restriction endonuclease analysis
in epidemiology of *Staphylococcus aureus* outbreak, 307–311
of *Staphylococcus aureus* plasmid DNA, 195–199
Rhesus monkey kidney cells, influenza virus inoculum in, 363–365
Rickettsia rickettsiae, cephalosporins against, 61
Rifampicin
amphotericin B synergy with, 21–34
coagulase-negative staphylococcal resistance to, 557–559
against pneumonia, 63
Rifampin
against mycobacteria, 169–171
against *Staphylococcus aureus*, 601–608
Ro 23-9424, against *Staphylococcus aureus*, 517–521
ROC curves. *See* Receiver operating curves
Roll-plate culture method, in diagnosis of central venous catheter-related infections, 13–20
Rosco PGUA/indole, for screening of *Escherichia coli*, 291–294
Rotavirus, in 2-year-old girl, 162
Roxithromycin
300 mg daily versus 150 mg b.i.d., 111S–117S
against acute community-acquired respiratory tract infections, 81S–84S
amoxicillin–clavulanic acid compared with, against respiratory tract infections, 85S–95S
cefaclor compared with, against respiratory tract infections, 97S–101S
clarithromycin compared with, against respiratory tract infections, 44, 47–49, 119S–122S
doxycycline compared with
against bronchitis, 123S–127S
against endocervical infections, 129S–131S
erythromycin compared with, against orodental infection, 133S–137S
in vitro activity of against *Moraxella catarrhalis*, 63S–65S
overview of, 61S–62S
penetration of into gum, 77S–79S
pharmacokinetics and dose scheduling of, 71S–76S
virulence of Gram-positive cocci and, 67S–70S
rRNA gene probe, *Staphylococcus aureus* chromosomal DNA hybridized with, 195–199
RU29246. *See* Cefdaloxime

Salmonella antigen O-6, monoclonal antibodies to, 213–223
Salmonella enteritidis, β-glucuronidase in, 291–294
Salmonella prosthetic valve endocarditis, overview of, 273–276
Salmonella spp.
cefotaxime against, 68–69
cefquinome against, 331–337
cephalosporins against, 61
lomefloxacin against, 339–343
Salmonella test, Welcolex, clinical evaluation of, 1–4
Salmonella typhi
serologic methods in diagnosis of, 651–656
in 2-year-old girl, 162–163
Saperconazole, against *Aspergillus* spp., 21–34
Satelliting streptococci, overview of, 185–194
Sepsis, pediatric, blood cultures in, 499–503
Septic arthritis, of hip, *Haemophilus influenzae*, type f in, 157–159
Septicemia
catheter-related, quantitative tip methods in diagnosis of, 13–20
α-hemolytic streptococci in, 185–194
incidence of, impact of converting to biphasic blood culture system on, 5–11
Septi-Chek biphasic blood culture system, in detection of pseudobacteremia, 5–11
Septi-Chek blood culture system, pediatric, evaluation of, 301–306
Serratia marcescens
cefdinir against, 537–543
cefotaxime against, 69
cefquinome against, 331–337
cephalosporins against, 73, 75–76, 78
fluoroquinolones against, 177–178
ofloxacin against, 425–434
Serratia plymuthica
in community-acquired bacteremia, 449–452
erythromycin against, 449–452
gentamicin against, 449–452
Serratia spp.
cefotaxime against, 68–69
resistance in, 3S–10S
Sexually transmitted diseases (STDs), clarithromycin against, 39–53
Shell vial centrifugation culture
Chlamydia trachomatis in, 355–357
herpes simplex virus in, 673–678
parainfluenza virus in, 669–672
Shigella dysenteriae 1 infection, rapid diagnosis of, 359–361
Shigella spp.
cefotaxime against, 68–69
cefquinome against, 331–337
β-glucuronidase in, 291–294
lomefloxacin against, 339–343

Shigella test, Welcolex, clinical evaluation of, 1–4
Sinusitis
  clarithromycin against, 39–53
  roxithromycin against, 81S–84S, 119S–122S
Skin/skin-structure infections
  cefotetan against, 595–600
  clarithromycin against, 39–53
  ofloxacin against, 425–439
  roxithromycin against, 111S–117S
Slide agglutination method, CL-1 and Cl-2 monoclonal antibodies against serogroup C_1 *Salmonella* assessed via, 213–223
SNAP probes. *See* Alkaline-phosphatase-labeled DNA probes
Sodium metaperiodate oxidation, Cl-1 and Cl-2 antibodies subject to, 213–223
Sodium polyanetholesulfonate (SPS)
  in BACTEC PEDS Plus medium, 225–231
  in blood culture media, 277–280, 301–306
Soft tissue infections
  clarithromycin against, 39–53
  roxithromycin against, 111S–117S
Sonication method, in diagnosis of central venous catheter-related infections, 13–20
Southern blot analysis, in latent human papillomavirus detection, 679–683
Sparfloxacin, against mycobacteria, 169–171
Spectrophotometry, in EIA of *Chlamydia trachomatis* in urogenital specimens, 663–668
SPS. *See* Sodium polyanetheolesulfonate
Staphylococci
  cefdinir against, 537–543
  cephalosporins against, 67–80
  clarithromycin/14-hydroxyclarithromycin against, 259–266
  E3709 against, 621–625
  fluoroquinolones against, 177
  in pediatric blood culture evaluation, 225–231
Staphylococci, coagulase-negative
  in BACTEC high blood volume resin media, 385–391
  biphasic blood culture system in detection of, 5–11
  cefotaxime against, 70, 87
  ceftriaxone against, 87
  clarithromycin against, 50
Staphylococci, groups A and B
  amoxicillin–clavulanic acid against, 141–144
  cefuroxime against, 141–144
  ciprofloxacin against, 141–144
  enoxacin against, 141–144
  L-ofloxacin against, 141–144
  ofloxacin against, 141–144
Staphylococcus aureus
  amoxicillin–clavulanic acid against, 141–144
  in BACTEC high blood volume resin media, 385–391
  biphasic blood culture system in detection of, 5
  cefotaxime against, 70, 86–88, 93–95
  ceftriaxone against, 86–88, 93, 95
  cefuroxime against, 141–144
  in central venous catheter-related infections, 15, 18
  cephalosporins against, 57–65, 73–77, 517–521
  cephamycins against, 517–521
  chromosomal DNA typing and, 195–199
  ciprofloxacin against, 141–144, 375–378, 613–620
  clarithromycin against, 45–47, 49–50
  cloxacillin against, 86
  CP-74,667 against, 613–620
  decaplanin against, 517–521
  enoxacin against, 141–144, 517–521
  E-test and, 465–468
  FCE 22101 against, 517–521
  fleroxacin against, 517–521
  fluorinated naphthyridines against, 517–521
  fluoroquinolones against, 178, 517–521, 601–608
  HRE 664 against, 517–521
  imipenem against, 517–521
  β-lactams against, 517–521
  lomefloxacin against, 393–398
  MDL 62211 against, 517–521
  meropenem against, 517–521
  mersacidin against, 517–521
  metal compounds against, 549–552
  methicillin-resistant, 207–211, 247–251, 601–608
  mupirocin against, 517–521
  nafcillin against, 166
  neonatal nursery outbreak of, 307–311
  norfloxacin against, 375–378, 517–521
  L-ofloxacin against, 141–144, 375–378
  ofloxacin against, 141–144, 517–521
  peptide/peptide-derivative compounds against, 517–521
  piperacillin against, 517–521
  quinolones against, 517–521
  ramoplanin against, 517–521
  rapid identification of, 295–300
  Ro 23-9424 against, 517–521
  roxithromycin against, 67S–70S
  tazobactam against, 517–521
  teicoplanin against, 517–521
  temafloxacin against, 393–398, 613–620
  tosufloxacin against, 613–620
  vancomycin against, 517–521
  WIN 57253 against, 517–521
Staphylococcus epidermidis
  cefotaxime against, 89, 93, 95
  ceftriaxone against, 89, 94–95
  in central venous catheter-related infections, 15, 18
  ciprofloxacin against, 375–378
  fluoroquinolones against, 177–178
  metal compounds against, 549–552
  norfloxacin against, 375–378
  L-ofloxacin against, 375–378
  trospectomycin against, 417–423
Staphylococcus haemolyticus
  mersacidin against, 641–644
  metal compounds against, 549–552
  vancomycin against, 641–644
Staphylococcus saprophyticus, metal compounds against, 549–552
Staphylococcus spp.
  cefdinir against, 537–543
  ciprofloxacin against, 531–536
  CP-74667 against, 531–536
  enoxacin against, 531–536
  norfloxacin against, 531–536
  ofloxacin against, 531–536
Stb assays, of pig *Escherichia coli* strains, 505–510
STDs. *See* Sexually transmitted diseases
Stool specimens, copepods in, 561–565
Streptococci
  Actinomyces pyogenes interaction with, 349–354
  in bacteremia, 151–155
  cefdinir against, 537–543
  E3709 against, 621–625
  genetic heterogeneity among, 281–285
  α-hemolytic, 185–194
  metal compounds against, 549–552
Streptococci, viridans group
  cefotaxime against, 70, 92, 95
  ceftriaxone against, 95
  cefuroxime against, 141–144
  ciprofloxacin against, 141–144
  clarithromycin against, 44
  enoxacin against, 141–144
  metal compounds against, 549–552
  L-ofloxacin against, 141–144
  ofloxacin against, 141–144
Streptococcus agalactiae
  cefotaxime against, 70
  clarithromycin against, 44
Streptococcus dysgalactiae, in bacteremia, 151–155
Streptococcus equi, in bacteremia, 151–155
Streptococcus equisimilis, in bacteremia, 151–155
Streptococcus faecalis, in central venous catheter-related infections, 16, 19
Streptococcus morbillorum, overview of, 185–194
Streptococcus pneumoniae
  amoxicillin–clavulanic acid against, 141–144
  cefaclor against, 633–640, 97S–101S
  cefepime against, 633–640
  cefixime against, 633–640
  cefotaxime against, 70, 81–84, 87, 93, 95
  cefprozil against, 633–640
  cefquinome against, 331–337
  ceftriaxone against, 81–84, 87, 94–95
  cefuroxime against, 141–144, 633–640
  cephalosporins against, 57–65, 74–76
  ciprofloxacin against, 141–144, 613–620
  clarithromycin against, 44–45, 47, 49
  CP-74,667 against, 613–620
  enoxacin against, 141–144
  L-ofloxacin against, 141–144
  ofloxacin against, 141–144
  rapid identification of, 295–300
  roxithromycin against, 67S–70S, 97S–101S
  temafloxacin against, 613–620
  tosufloxacin against, 613–620
Streptococcus pyogenes
  cefotaxime against, 70

cephalosporins against, 61
ciprofloxacin against, 613–620
clarithromycin against, 44–45, 47, 49–50
CP-74,667 against, 613–620
roxithromycin against, 67S–70S
temafloxacin against, 613–620
tosufloxacin against, 613–620
Streptococcus zooepidemicus, in bacteremia, 151–155
Streptolysins, roxithromycin effect on biosynthesis of, 67S–70S
Strongyloides stercoralis, cephalosporins against, 61
Structural virulence factor, roxithromycin effect on biosynthesis of, 67S–70S
Subauricular abscess, α-hemolytic streptococci in, 185–194
Subclavian catheters, infections of, quantitative tip culture methods in diagnosis of, 15
Sulbactam
against *Bacteroides fragilis*, 321–330
against *Chlamydia trachomatis*, 371–373
sulfamethoxazole, against acute diarrhea, 339–343
Surgical wound infections, *Aspergillus fumigatus* in, 703–706
Suspension test, in herpes simplex virus detection, 673–678
Swan–Ganz catheters, infections of, quantitative tip methods in diagnosis of, 15
Symex reagents, in detection of parainfluenza viruses, 669–672
Syngene DNA–DNA probes, for identification of *Mycobacterium tuberculosis* complex and *Mycobacterium avium* complex, 657–662
Syva enzyme immunoassay, of *Chlamydia trachomatis* in urogenital specimens, 663–668
Syva MicroTrak assay, of *Chlamydia trachomatis* from endocervical swabs, 579–586

Tazobactam
against *Bacteroides fragilis*, 321–330
against *Staphylococcus aureus*, 517–521
TE-031. *See* Clarithromycin
Teicoplanin
broth microdilution susceptibility testing of, 609–612
diffusion of in agar, 253–258
disk diffusion susceptibility testing of, 609–612
against *Staphylococcus aureus*, 247–251, 517–521, 601–608
TEM. *See* Transmission electron microscopy
Temafloxacin
against *Bacteroides fragilis*, 613–620
intracellular penetration of, 393–398
against *Pseudomonas aeruginosa*, 613–620
against *Staphylococcus aureus*, 613–620
against *Streptococcus pneumoniae*, 613–620
against *Streptococcus pyogenes*, 613–620
Tetracycline
against acute diarrhea, 339–343
against *Campylobacter jejuni*, 469–472
against *Moraxella catarrhalis*, 63S–65S
against pneumococci, 473–478
against *Staphylococcus aureus*, 601–608
Thiol-dependent streptococci
genetic heterogeneity among, 281–285
overview of, 185–194
Ticarcillin, against *Bacteroides fragilis*, 321–330
Ticarcillin–clavulanate
against *Aeromonas* spp., 453–455
against *Vibrio* spp., 453–455
Tissue culture cells
lomefloxacin in, 393–398
temafloxacin in, 393–398
TMP/SMZ. *See* 81S–84S, 119S–122S
Tosufloxacin
against *Bacteroides fragilis*, 613–620
against *Pseudomonas aeruginosa*, 613–620
against *Staphylococcus aureus*, 613–620
against *Streptococcus pneumoniae*, 613–620
against *Streptococcus pyogenes*, 613–620
Toxin B assay, in diagnosis of *Clostridium difficile*-associated diarrhea, 493–498
Toxoplasma gondii
cephalosporins against, 61
clarithromycin against, 46
Toxoplasma-specific IgM, antibody-capture EIA for detection of, 587–593
Transmission electron microscopy (TEM), of α-hemolysin-deficient streptococci, 185–194
Treponema pallidum, clarithromycin against, 46
Tricuspid valve endocarditis, *Salmonella* spp. in, 273–276
Trifluoroquinolones. *See* Temafloxacin
Trimethoprim, against acute diarrhea, 339–343
Trimethoprim–sulfamethoxazole (TMP/SMZ)
against *Moraxella catarrhalis*, 63S–65S
against *Pneumocystis* pneumonia, 129–134
against *Staphylococcus aureus*, 601–608
Trospectomycin
against *Bacteroides fragilis*, 417–423
against *Enterococcus faecalis*, 417–423
against *Escherichia coli*, 417–423
against *Haemophilus influenzae*, 417–423, 693–701
against *Moraxella catarrhalis*, 417–423
against *Neisseria gonorrhoeae*, 417–423, 627–632
against *Staphyococcus epidermidis*, 417–423
Tuberculosis, pneumonia associated with, 57–65
Typhoid fever, diagnosis of by serologic methods, 651–656

United States Consensus Panel, on antimicrobial resistance, 49S–52S
Ureaplasma urealyticum, endocervical
doxycycline against, 129S–131S
roxithromycin against, 129S–131S
Urethritis, α-hemolytic streptococci in, 185–194
Urinary tract infections
Chlamydia trachomatis in, 663–668
ofloxacin against, 425–439
Urine culture, routine
blood agar in, 287–290
CLED agar in, 287–290
MacConkey agar in, 287–290
Urosepsis, *Escherichia coli*, DNA fingerprinting in, 399–405

Vacutainer supplemented peptone broth tube, Septi-Chek blood culture system compared with, 301–306
Vaginosis, bacterial, trospectomycin against, 417–423
Vancomycin
diffusion of in agar, 253–258
against *Enterococcus* spp., 459–463
against *Leuconostoc* spp., 641–644
against *Pediococcus* spp., 641–644
against pneumonia, 63–64
against *Staphylococcus aureus*, 247–251, 517–521, 601–608
against *Staphylococcus haemolyticus*, 641–644
Vibrio cholerae, in 2-year-old girl, 161–164
Vibrio spp.
ciprofloxacin against, 453–455
gentamicin against, 453–455
imipenem against, 453–455
lomefloxacin against, 339–343
meropenem against, 453–455
ticarcillin–clavulanate against, 453–455

Welcolex Colour *Salmonella* and *Shigella* tests, clinical evaluation of, 1–4
Western blot analysis, of HTLV-I sera from rural Haiti, 123
Widal test, in diagnosis of typhoid fever, 651–656
WIN 57273
against mycobacteria, 169–171
against *Staphylococcus aureus*, 517–521, 601–608
Wounds, penicillin-resistant enterococci in, 31S–35S
WR238605 1, against *Pneumocystis* pneumonia, 131

Xanthomonas maltophilia
cefdinir against, 537–543
cefotaxime against, 69, 87
ceftriaxone against, 87
ciprofloxacin against, 531–536
CP-74667 against, 531–536
enoxacin against, 531–536
norfloxacin against, 531–536
ofloxacin against, 531–536
Xylose, *Actinomyces pyogenes* ability to produce acid from, 349–354

Yeast, in blood cultures, 233–237
Yersinia enterocolitica
cefotaxime against, 68
lomefloxacin against, 339–343
Yersinia pestis, cephalosporins against, 57–65

Z break points, determination of, 135–140
Zymosan, opsonized, PMN association of quinolones increased by, 393–398